Program
Biological Products
Also written as “Biological”, “AAV2-GDNF gene therapy” and “Biological/Vaccine: BNT162b2 10mcg”.
Its studies are mostly in Parkinson Disease · COVID-19 · Diabetes Mellitus, Type 1 · Carcinoma, Renal Cell · Metabolic Diseases, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immune Cell | 22 open or running | phase 1since Dec 6, 2017 | Dec 6, 2017 | none ahead |
| Anchiano Therapeutics Israel | 10 open or running | phase 2since Aug 8, 2011 | Aug 8, 2011 | none ahead |
| Bayer | 11 open or running | phase 2since Feb 14, 2024 | Feb 14, 2024 | Aug 31, 2028phase 2 · NCT06285643 |
| BioNTech | 10 open or running | phase 3since Mar 19, 2021 | Mar 19, 2021 | none ahead |
| diavacs-inc | 10 open or running | phase 2since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| GAIA BioMedicine | 10 open or running | phase 2since Nov 19, 2021 | Nov 19, 2021 | none ahead |
| Lisata Therapeutics | 10 open or running | phase 1since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| Longeveron | 10 open or running | phase 2since Oct 23, 2015 | Oct 23, 2015 | none ahead |
| Sanofi | 11 open or running | phase 1since Nov 24, 2025 | Nov 24, 2025 | none ahead |
| Sinopharm | 10 open or running | phase 2since Jun 11, 2020 | Jun 11, 2020 | none ahead |
| Vertex Pharmaceuticals | 11 open or running | phase 3since Feb 13, 2025 | Feb 13, 2025 | none ahead |
Also a collaborator on its studies: Pfizer, chengdu-institute-of-biological-products-co-ltd and simoon-record-pharma-information-consulting-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2001First study: phase 1 study in Kidney NeoplasmsNew to Lisata TherapeuticsLisata Therapeutics · NCT00014131 · 9 enrolled · United States
- Aug 8, 2011Anchiano Therapeutics Israel's first study: phase 2 study in AdenocarcinomaNew to Anchiano Therapeutics IsraelAnchiano Therapeutics Israel · NCT01413087 · 12 enrolled · United States, Israel
- Sep 18, 2013diavacs-inc's first study: phase 2 study in Treatment of Type I Diabetes Mellitus.New to diavacs-incdiavacs-inc · NCT01947569 · 90 enrolled · United States
- Oct 23, 2015Longeveron's first study: phase 2 study in Metabolic DiseasesNew to LongeveronLongeveron · NCT02587572
- Dec 6, 2017Immune Cell's first studies: 2 phase 1 studiesNew to Immune CellImmune Cell · NCT03383965, NCT03383952
- Jun 11, 2020Sinopharm's first study: phase 2 study in Papillomavirus InfectionsNew to SinopharmSinopharm · NCT04436133 · 480 enrolled · China
- Mar 19, 2021BioNTech's first study: phase 3 study in COVID-19New to BioNTechBioNTech · NCT04816643 · 11,837 enrolled · United States, Brazil, Finland and more
- Nov 19, 2021GAIA BioMedicine's first study: phase 2 study in Cell TherapyNew to GAIA BioMedicineGAIA BioMedicine · NCT05207371 · 22 enrolled · Japan
- Feb 14, 2024Bayer's first study: phase 2 study in Parkinson DiseaseNew to BayerBayer · NCT06285643 · 59 enrolled · United States, Germany, Poland and more
- Feb 13, 2025Vertex Pharmaceuticals's first study: phase 3 study in Diabetes Mellitus, Type 1New to Vertex PharmaceuticalsVertex Pharmaceuticals · NCT06832410 · 10 planned · United States, Canada, Saudi Arabia
- Nov 24, 2025Sanofi's first study: phase 1 study in Lower Respiratory Tract DiseaseNew to SanofiSanofi · NCT07295028 · 240 enrolled · Australia
Ahead
- Aug 31, 2028Primary completion: phase 2 study in Parkinson DiseaseBayer · NCT06285643
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07295028Lower Respiratory Tract Disease · Australia | 1 | Active, not recruiting | Sanofi | Apr 21, 2026 | 240 |
| NCT06832410Diabetes Mellitus, Type 1 · United States, Canada, Saudi Arabia | 3 | Recruiting | Vertex Pharmaceuticals | Sep 17, 2026 | 10 |
| NCT06285643Parkinson Disease · United States, Germany, Poland and more | 2 | Active, not recruiting | Bayer | Aug 31, 2028 | 59 |
| NCT05207371Cell Therapy · Japan | 2 | Terminated | GAIA BioMedicine | Sep 1, 2024 | 22 |
| NCT04816643COVID-19 · United States, Brazil, Finland and more | 3 | Completed | BioNTech | Oct 4, 2023 | 11,837 |
| NCT04436133Papillomavirus Infections · China | 2 | Completed | Sinopharm | Mar 1, 2022 | 480 |
| NCT03383965Hodgkin Disease · China | 1 | Recruiting | Immune Cell | Dec 31, 2020 | 20 |
| NCT03383952Leukemia, B-Cell · China | 1 | Recruiting | Immune Cell | Dec 31, 2020 | 20 |
| NCT02587572Metabolic Diseases | 2 | Withdrawn | Longeveron | Dec 2023 | 0 |
| NCT01947569Treatment of Type I Diabetes Mellitus. · United States | 2 | UNKNOWN | diavacs-inc | Nov 2014 | 90 |
| NCT01413087Adenocarcinoma · United States, Israel | 2 | Terminated | Anchiano Therapeutics Israel | Jan 2013 | 12 |
| NCT00014131Kidney Neoplasms · United States | 1 | Terminated | Lisata Therapeutics | Dec 2009 | 9 |
How it is read
Names in the registry
- “Biological”, 2 entries
- “AAV2-GDNF gene therapy”, 1 entry
- “Biological/Vaccine: BNT162b2 10mcg”, 1 entry
- “Biological/Vaccine: BNT162b2 3mcg”, 1 entry
- “Biological/Vaccine: monovalent (hMPV) unlicensed comparator”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
- COVID-19, 1 study
- Diabetes Mellitus, Type 1, 1 study
- Carcinoma, Renal Cell, 1 study
- Metabolic Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.